Bruker/$BRKR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Ticker

$BRKR
Sector
Primary listing

Employees

11,396

Bruker Metrics

BasicAdvanced
$5.2B
66.36
$0.52
1.20
$0.20
0.58%

What the Analysts think about Bruker

Analyst ratings (Buy, Hold, Sell) for Bruker stock.

Bulls say / Bears say

Q1 2025 revenue reached $801.4 million, up 11.0% year-over-year, driven by 2.9% total organic growth and 5.1% organic growth in the core BSI segment (Business Wire).
Bruker rolled out a cost reduction plan aimed at cutting annual expenses by $100 million to $120 million in fiscal 2026, supporting efforts to expand margins and grow EPS despite softening demand (Business Wire).
Bruker secured more than $27 million in multi-year contracts for explosives and chemical trace detection solutions in aviation security and defense, diversifying its revenues and strengthening recurring consumables and service revenue streams (Business Wire).
Organic revenue decreased 7.0% year-over-year in Q2 2025, revealing ongoing weak demand in the U.S. academic, biopharma, and industrial sectors (Business Wire).
Bruker revised its full-year 2025 non-GAAP EPS forecast downward to $1.95–$2.05 from $2.40–$2.48, versus $2.41 in fiscal 2024, indicating sustained profit challenges and ongoing demand uncertainty (Business Wire).
Bruker’s cash and cash equivalents declined to $92 million at the end of Q2 2025, while total long-term debt increased to $2.44 billion, raising the company’s leverage and potential interest expense (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

Bruker Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Bruker Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BRKR

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Bruker stock | $BRKR Share Price | Lightyear